“…Claims for prescribed medications were evaluated for all CD patients in the study following each patient's IDD, as defined previously. Therapies recommended or commonly prescribed to treat iMCD based on published clinical guidelines 6,7 and natural history studies 11 were queried in the database and grouped under six therapeutic categories: (1) chemotherapy (bortezomib, bendamustine, bleomycin, cisplatin, cyclophosphamide, dacarbazine, decitabine, doxorubicin etoposide, lenalidomide, thalidomide, vinblastine, and vincristine); (2) immunomodulators (anakinra, cyclosporine, eculizumab, hydroxychloroquine, mycophenolate mofetil, and sirolimus); (3) B cell depleting agents (rituximab); (4) direct IL-6 inhibitors (siltuximab); (5) corticosteroids; and (6) IL-6 receptor inhibitors (tocilizumab). Of these queried therapeutics, those that were identified in this patient population are detailed in Supplementary Table 2.…”